Page 106 - Genentech News Today

With the rise of mRNA-based treatments, the field of oncology is about to go through a significant change.

Imugene Ltd (ASX:IMU, OTC:IUGNF) has brought on board Dr John Byon as senior vice president of Clinical Development to further the company’s development of...

UK NHS to offer under the skin injection for cancer treatment, reducing treatment times significantly

ALINA data demonstrate Alecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced settingAbout half

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), said Friday that the Phase III ALINA study, which evaluated Alecensa or alectinib in a...

– ALINA data demonstrate Alecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced setting –– About half of people with NSCLC experience disease recurrence following surgery, despite adjuvant chem...

In the early 1980s, a California company pioneered a lucrative new industry. A few North Carolina leaders were paying attention.

Science withdrew two influential papers for which the now-former Stanford president served as principal author, despite objections from Elke Stein, the postdoc who conducted most of the work

Adjuvant treatment with alectinib generated a statistically significant and clinically meaningful improvement in disease-free survival compared with platinum-based chemotherapy in patients with completely resected stage IB to IIIA, ALK-positive non–small cell lung cancer.

Recursion Pharmaceuticals uses machine learning to develop drugs with Bayer and Genentech. CEO Chris Gibson thinks proceeding with that work outweighs any risks a moratorium might prevent.